ENZN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ENZN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-29), Enzon Pharmaceuticals's current share price is $0.08345. Enzon Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $0.18. Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is 0.46.
The historical rank and industry rank for Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
During the past years, Enzon Pharmaceuticals's highest Cyclically Adjusted Price-to-FCF was 9.32. The lowest was 0.30. And the median was 1.24.
ENZN's Cyclically Adjusted Price-to-FCF is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Enzon Pharmaceuticals's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $0.006. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $0.18 for the trailing ten years ended in Dec. 2023.
The historical data trend for Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzon Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | 1.15 | 1.22 | 0.93 | 0.75 | 0.51 |
For the Biotechnology subindustry, Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF for today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 0.08345 | / | 0.18 | |
= | 0.46 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzon Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Enzon Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 0.006 | / | 129.4194 | * | 129.4194 | |
= | 0.006 |
Current CPI (Dec. 2023) = 129.4194.
Enzon Pharmaceuticals Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201403 | 0.185 | 99.695 | 0.240 |
201406 | 0.150 | 100.560 | 0.193 |
201409 | 0.170 | 100.428 | 0.219 |
201412 | 0.226 | 99.070 | 0.295 |
201503 | 0.105 | 99.621 | 0.136 |
201506 | 0.095 | 100.684 | 0.122 |
201509 | 0.076 | 100.392 | 0.098 |
201512 | 0.056 | 99.792 | 0.073 |
201603 | -0.044 | 100.470 | -0.057 |
201606 | 0.034 | 101.688 | 0.043 |
201609 | 0.038 | 101.861 | 0.048 |
201612 | 0.031 | 101.863 | 0.039 |
201703 | 0.010 | 102.862 | 0.013 |
201706 | 0.071 | 103.349 | 0.089 |
201709 | -0.006 | 104.136 | -0.007 |
201712 | 0.071 | 104.011 | 0.088 |
201803 | -0.005 | 105.290 | -0.006 |
201806 | -0.006 | 106.317 | -0.007 |
201809 | -0.005 | 106.507 | -0.006 |
201812 | -0.005 | 105.998 | -0.006 |
201903 | -0.007 | 107.251 | -0.008 |
201906 | -0.004 | 108.070 | -0.005 |
201909 | 0.150 | 108.329 | 0.179 |
201912 | 0.017 | 108.420 | 0.020 |
202003 | -0.007 | 108.902 | -0.008 |
202006 | 0.017 | 108.767 | 0.020 |
202009 | -0.007 | 109.815 | -0.008 |
202012 | -0.008 | 109.897 | -0.009 |
202103 | 0.001 | 111.754 | 0.001 |
202106 | 0.000 | 114.631 | 0.000 |
202109 | -0.004 | 115.734 | -0.004 |
202112 | -0.003 | 117.630 | -0.003 |
202203 | -0.003 | 121.301 | -0.003 |
202206 | -0.009 | 125.017 | -0.009 |
202209 | 0.001 | 125.227 | 0.001 |
202212 | 0.002 | 125.222 | 0.002 |
202303 | 0.002 | 127.348 | 0.002 |
202306 | 0.003 | 128.729 | 0.003 |
202309 | 0.006 | 129.860 | 0.006 |
202312 | 0.006 | 129.419 | 0.006 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Enzon Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Randolph C Read | director | C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022 |
Jaffrey Adam Firestone | director | C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479 |
Family Fund Couchman | other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Jordan Bleznick | director | C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016 |
Pearce Michael Cooper | other: See explanation of responses | 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517 |
Harper Asset Management Llc | other: See explanation of responses | 2945 S CENTER GREEN CT, G215, BOULDER CO 80301 |
Brian James Harper | other: See explanation of responses | 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301 |
Myrexis, Inc. | other: See Footnote 1 | 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020 |
Xstelos Corp. | other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Jonathan Couchman | 10 percent owner, other: See Footnote 1 | 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020 |
Carl C Icahn | 10 percent owner | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160 |
Richard L Feinstein | officer: VP-Finance and PFO | |
Jonathan Christodoro | director | C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160 |
Kostas D Odysseas | director | 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830 |
Jennifer Isacoff Mcnealey | director | C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121 |
From GuruFocus
By Marketwired Marketwired • 09-03-2020
By gurufocus 10qk • 03-16-2011
By Marketwired Marketwired • 10-22-2020
By gurufocus 10qk • 08-09-2010
By gurufocus Todd Sullivan • 03-14-2008
By GuruFocus Research GuruFocus Editor • 06-22-2010
By Marketwired Marketwired • 01-04-2021
By Sydnee Gatewood Sydnee Gatewood • 12-02-2016
By gurufocus 10qk • 11-04-2009
By Marketwired Marketwired • 08-22-2020